A detailed history of Penserra Capital Management LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Penserra Capital Management LLC holds 102 shares of GILD stock, worth $6,976. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102
Previous 5,767 98.23%
Holding current value
$6,976
Previous $466,000 98.5%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $405,500 - $494,497
-5,665 Reduced 98.23%
102 $7,000
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $88,656 - $100,538
-1,210 Reduced 17.34%
5,767 $466,000
Q3 2023

Nov 15, 2023

SELL
$73.94 - $80.67 $81,703 - $89,140
-1,105 Reduced 13.67%
6,977 $522,000
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $581,248 - $662,994
7,647 Added 1757.93%
8,082 $622,000
Q1 2023

Apr 24, 2023

SELL
$77.31 - $88.08 $2.7 Million - $3.07 Million
-34,901 Reduced 98.77%
435 $35,000
Q4 2022

Feb 13, 2023

BUY
$62.32 - $89.47 $2.2 Million - $3.16 Million
35,336 New
35,336 $3.03 Million
Q4 2018

Feb 06, 2019

SELL
$60.54 - $79.0 $278,484 - $363,400
-4,600 Closed
0 $0
Q3 2018

Nov 05, 2018

BUY
$71.28 - $78.92 $46,332 - $51,298
650 Added 16.46%
4,600 $355,000
Q2 2018

Aug 13, 2018

BUY
$64.88 - $75.68 $9,732 - $11,352
150 Added 3.95%
3,950 $279,000
Q1 2018

May 08, 2018

BUY
$72.84 - $88.8 $21,852 - $26,640
300 Added 8.57%
3,800 $286,000
Q4 2017

Feb 07, 2018

BUY
$71.15 - $83.52 $39,132 - $45,936
550 Added 18.64%
3,500 $250,000
Q3 2017

Oct 26, 2017

BUY
$72.11 - $85.47 $25,238 - $29,914
350 Added 13.46%
2,950 $246,000
Q2 2017

Aug 21, 2017

BUY
N/A
2,600
2,600 $184,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Penserra Capital Management LLC Portfolio

Follow Penserra Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penserra Capital Management LLC with notifications on news.